Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767392 | 0.90 | HIF1A (0.68) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL4400208 | 0.90 | HIF1A (0.71) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL14303441 | 0.90 | HIF1A (0.68) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL14303440 | 0.88 | L3MBTL1 (0.64) | L3MBTL1HIF1AALDH1A1LMNATSHR | |
| SCHEMBL4781771 | 0.88 | HIF1A (0.66) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL4507484 | 0.87 | L3MBTL1 (0.61) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL1592824 | 0.86 | L3MBTL1 (0.60) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL13789634 | 0.85 | L3MBTL1 (0.58) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL12610042 | 0.84 | HIF1A (0.86) | L3MBTL1HIF1AALDH1A1LMNAPKM | |
| SCHEMBL1592847 | 0.83 | ALDH1A1 (0.57) | L3MBTL1HIF1AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | L3MBTL1 628/4885HIF1A 910/4885ALDH1A1 2256/4885 |
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | L3MBTL1 4245/4885HIF1A 928/4885ALDH1A1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.